These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33917071)

  • 1. Lassa Virus Treatment Options.
    Hansen F; Jarvis MA; Feldmann H; Rosenke K
    Microorganisms; 2021 Apr; 9(4):. PubMed ID: 33917071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
    Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current research for a vaccine against Lassa hemorrhagic fever virus.
    Warner BM; Safronetz D; Stein DR
    Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.
    Hulseberg CE; Fénéant L; Szymańska-de Wijs KM; Kessler NP; Nelson EA; Shoemaker CJ; Schmaljohn CS; Polyak SJ; White JM
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30700611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation.
    Maruyama J; Manning JT; Mateer EJ; Sattler R; Bukreyeva N; Huang C; Paessler S
    mSphere; 2019 Sep; 4(5):. PubMed ID: 31554720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical development of a vaccine against Lassa fever.
    Banadyga L; Stein DR; Qiu X; Safronetz D
    Can Commun Dis Rep; 2018 Jun; 44(6):139-147. PubMed ID: 31015807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine platforms to control Lassa fever.
    Lukashevich IS; Pushko P
    Expert Rev Vaccines; 2016 Sep; 15(9):1135-50. PubMed ID: 27136941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal Models of Lassa Fever.
    Sattler RA; Paessler S; Ly H; Huang C
    Pathogens; 2020 Mar; 9(3):. PubMed ID: 32155851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of antiviral therapeutics in animal models of Lassa fever.
    Warner BM; Siragam V; Stein DR
    Curr Opin Virol; 2019 Aug; 37():84-90. PubMed ID: 31357140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary and emerging pharmacotherapeutic agents for the treatment of Lassa viral haemorrhagic fever disease.
    Joseph AA; Fasipe OJ; Joseph OA; Olatunji OA
    J Antimicrob Chemother; 2022 May; 77(6):1525-1531. PubMed ID: 35296886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine platforms for the prevention of Lassa fever.
    Purushotham J; Lambe T; Gilbert SC
    Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody therapy for Lassa fever.
    Cross RW; Hastie KM; Mire CE; Robinson JE; Geisbert TW; Branco LM; Ollmann Saphire E; Garry RF
    Curr Opin Virol; 2019 Aug; 37():97-104. PubMed ID: 31401518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lassa virus diversity and feasibility for universal prophylactic vaccine.
    Lukashevich IS; Paessler S; de la Torre JC
    F1000Res; 2019; 8():. PubMed ID: 30774934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROSPECTS OF LASSA FEVER CANDIDATE VACCINES.
    Isaac AB; Karolina W; Temitope AA; Anuska R; Joanne E; Deborah A; Bianca OC; Filip T; Zofia P; Oluwasegun OI; Oluwaferanmi O; Grace BT
    Afr J Infect Dis; 2022; 16(2 Suppl):46-58. PubMed ID: 36124324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis.
    Oppliger J; Torriani G; Herrador A; Kunz S
    J Virol; 2016 Jul; 90(14):6412-6429. PubMed ID: 27147735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library.
    Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunobiology of Ebola and Lassa virus infections.
    Prescott JB; Marzi A; Safronetz D; Robertson SJ; Feldmann H; Best SM
    Nat Rev Immunol; 2017 Mar; 17(3):195-207. PubMed ID: 28111475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques.
    Cashman KA; Wilkinson ER; Zeng X; Cardile AP; Facemire PR; Bell TM; Bearss JJ; Shaia CI; Schmaljohn CS
    mBio; 2018 Oct; 9(5):. PubMed ID: 30377282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lassa fever diagnostics: past, present, and future.
    Happi AN; Happi CT; Schoepp RJ
    Curr Opin Virol; 2019 Aug; 37():132-138. PubMed ID: 31518896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.